Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1366560 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Structural modifications of the initial lead, 3-aminochroman (4), led to the identification of a novel series of pyridyl-fused amino chroman derivatives (5–8) and the structural isomers (9–12). The compounds described were evaluated for dual 5-HT transporter inhibitory and 5-HT1A receptor activities. The design strategy, synthesis, and in vitro biological characterization for these novel compounds are described.
Graphical abstractStructural modifications of the initial lead, 3-aminochroman (4), led to the identification of a novel series of pyridyl-fused amino chroman derivatives (5–8) and the structural isomers (9–12). The compounds described were evaluated for dual 5-HT transporter inhibitory and 5-HT1A receptor activities. The design strategy, synthesis, and in vitro biological characterization for these novel compounds are described.Figure optionsDownload full-size imageDownload as PowerPoint slide